STAT-1 Knockout Mice as a Model for Wild-Type Sudan Virus (SUDV).
Amides
/ therapeutic use
Animals
Antibodies, Viral
/ blood
Antiviral Agents
/ therapeutic use
Disease Models, Animal
Ebolavirus
/ classification
Female
Hemorrhagic Fever, Ebola
/ drug therapy
Male
Mice
Mice, Knockout
Pyrazines
/ therapeutic use
STAT1 Transcription Factor
/ genetics
Viral Proteins
/ genetics
STAT-1 knockout mice
SUDV
animal model
ebolavirus
filovirus
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
17 07 2021
17 07 2021
Historique:
received:
18
06
2021
revised:
14
07
2021
accepted:
16
07
2021
entrez:
10
8
2021
pubmed:
11
8
2021
medline:
19
11
2021
Statut:
epublish
Résumé
Currently there is no FDA-licensed vaccine or therapeutic against Sudan ebolavirus (SUDV) infections. The largest ever reported 2014-2016 West Africa outbreak, as well as the 2021 outbreak in the Democratic Republic of Congo, highlight the critical need for countermeasures against filovirus infections. A well-characterized small animal model that is susceptible to wild-type filoviruses would greatly add to the screening of antivirals and vaccines. Here, we infected signal transducer and activator of transcription-1 knock out (STAT-1 KO) mice with five different wildtype filoviruses to determine susceptibility. SUDV and Marburg virus (MARV) were the most virulent, and caused 100% or 80% lethality, respectively. Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Taï Forest ebolavirus (TAFV) caused 40%, 20%, and no mortality, respectively. Further characterization of SUDV in STAT-1 KO mice demonstrated lethality down to 3.1 × 10
Identifiants
pubmed: 34372594
pii: v13071388
doi: 10.3390/v13071388
pmc: PMC8310124
pii:
doi:
Substances chimiques
Amides
0
Antibodies, Viral
0
Antiviral Agents
0
Pyrazines
0
STAT1 Transcription Factor
0
Stat1 protein, mouse
0
Viral Proteins
0
favipiravir
EW5GL2X7E0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Références
J Infect Dis. 2018 Nov 22;218(suppl_5):S649-S657
pubmed: 29982696
Front Microbiol. 2013 Sep 05;4:267
pubmed: 24046765
Virus Res. 2010 Oct;153(1):121-33
pubmed: 20654661
Viruses. 2012 Oct 15;4(10):2115-36
pubmed: 23202456
Clin Vaccine Immunol. 2008 Mar;15(3):460-7
pubmed: 18216185
Antiviral Res. 2018 Mar;151:97-104
pubmed: 29289666
J Comp Pathol. 2001 Nov;125(4):243-53
pubmed: 11798241
J Pathol. 2015 Jan;235(2):153-74
pubmed: 25297522
Arch Virol Suppl. 2008;20:13-360
pubmed: 18637412
J Gen Virol. 2001 Jun;82(Pt 6):1365-1373
pubmed: 11369881
J Infect Dis. 2015 Oct 1;212 Suppl 2:S305-15
pubmed: 26038397
Clin Vaccine Immunol. 2010 Apr;17(4):572-81
pubmed: 20181765
J Virol. 2015 Oct 21;90(1):392-9
pubmed: 26491156
Genome Biol. 2014;15(11):540
pubmed: 25416632
Antiviral Res. 2014 Apr;104:153-5
pubmed: 24462697
Antiviral Res. 2018 Mar;151:39-49
pubmed: 29369776
Virology. 2014 Mar;452-453:324-33
pubmed: 24461913
Antiviral Res. 2019 Oct;170:104529
pubmed: 31195019
J Infect Dis. 2013 Jan 15;207(2):306-18
pubmed: 23045629
Adv Virus Res. 2018;100:189-221
pubmed: 29551136
J Virol. 2009 Apr;83(8):3810-5
pubmed: 19211761
Viruses. 2012 Sep;4(9):1477-508
pubmed: 23170168
J Infect Dis. 2011 Nov;204 Suppl 3:S968-72
pubmed: 21987777
FEMS Microbiol Rev. 2016 Jul;40(4):494-519
pubmed: 27268907
J Infect Dis. 2011 Nov;204 Suppl 3:S986-90
pubmed: 21987780
Antiviral Res. 2014 May;105:17-21
pubmed: 24583123
J Med Microbiol. 2012 Jan;61(Pt 1):8-15
pubmed: 21852521
J Mol Biol. 2016 Aug 28;428(17):3449-66
pubmed: 27189922
J Infect Dis. 2018 Nov 22;218(suppl_5):S466-S470
pubmed: 29878131
J Immunol. 2000 Apr 15;164(8):4220-8
pubmed: 10754318
Viruses. 2019 Feb 03;11(2):
pubmed: 30717492
J Virol. 2009 Jul;83(14):7296-304
pubmed: 19386702
J Virol. 2009 Jul;83(13):6404-15
pubmed: 19369350
Rev Med Virol. 2010 Nov;20(6):344-57
pubmed: 20658513
Med Trop (Mars). 1999;59(2):201-4
pubmed: 10546197
Adv Virol. 2016;2016:8059607
pubmed: 26989413
J Infect Dis. 1999 Feb;179 Suppl 1:S248-58
pubmed: 9988191
J Virol. 2014 Nov;88(21):12703-14
pubmed: 25142608
J Virol. 2006 Jul;80(13):6497-516
pubmed: 16775337
J Infect Dis. 2015 Oct 1;212 Suppl 2:S282-94
pubmed: 25943199
PLoS One. 2015 Sep 30;10(9):e0137786
pubmed: 26422247
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29133569
PLoS Pathog. 2009 Jul;5(7):e1000536
pubmed: 19649327
N Engl J Med. 2006 Aug 31;355(9):909-19
pubmed: 16943403
JCI Insight. 2019 Nov 1;4(21):
pubmed: 31550241
Lancet. 2011 Mar 5;377(9768):849-62
pubmed: 21084112
Annu Rev Pathol. 2017 Jan 24;12:387-418
pubmed: 27959626
J Infect Dis. 2018 Nov 22;218(suppl_5):S438-S447
pubmed: 30192975
J Virol. 2017 Aug 10;91(17):
pubmed: 28615211
J Infect Dis. 2018 Nov 22;218(suppl_5):S418-S422
pubmed: 30060231
Antiviral Res. 2018 Mar;151:50-54
pubmed: 29289664
Antiviral Res. 2015 Nov;123:70-7
pubmed: 26343011
J Infect Dis. 2018 Nov 22;218(suppl_5):S453-S457
pubmed: 29878128
Vet Pathol. 2015 Jan;52(1):21-5
pubmed: 24829285
Sci Rep. 2016 Jan 13;6:19193
pubmed: 26758505
Emerg Infect Dis. 2003 Dec;9(12):1531-7
pubmed: 14720391
J Infect Dis. 1999 Feb;179 Suppl 1:S120-6
pubmed: 9988175
PLoS Med. 2018 Mar 27;15(3):e1002535
pubmed: 29584730
Nat Microbiol. 2016 Aug 22;1(10):16142
pubmed: 27670117
Viruses. 2012 Dec 03;4(12):3468-93
pubmed: 23207275
Viruses. 2018 May 26;10(6):
pubmed: 29861435
J Infect Dis. 2015 Oct 1;212 Suppl 2:S404-9
pubmed: 26022440
J Infect Dis. 2011 Nov;204 Suppl 3:S796-9
pubmed: 21987753
J Infect Dis. 2016 Oct 15;214(suppl 3):S268-S274
pubmed: 27471321
Curr Opin Virol. 2017 Feb;22:51-58
pubmed: 28012412
Oncotarget. 2017 Jul 11;8(28):46262-46272
pubmed: 28545034